Palvella Therapeutics (FRA:PI6) Tax Provision: €0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PI6 Palvella Therapeutics Inc FRA:PI6
20 GF Score
Price €125.00
! 2 Warning Signs
View Full Analysis

What is Palvella Therapeutics Tax Provision?

Palvella Therapeutics FRA:PI6 +1.63% 20 Tax Provision is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:PI6 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Palvella Therapeutics's tax provision for the three months ended in Mar. 2026 was €0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Palvella Therapeutics Tax Provision Historical Data

* Premium members only.

The historical data trend for Palvella Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palvella Therapeutics Tax Provision Chart

Palvella Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Tax Provision
0.97 0.00 0.00 0.00

Palvella Therapeutics Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:PI6
20GF Score
Palvella Therapeutics Inc FRA:PI6
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Palvella Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of €0.00 Mil mean?
Palvella Therapeutics (FRA:PI6) has a Tax Provision of €0.00 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Palvella Therapeutics and its competitors.
Is Palvella Therapeutics' Tax Provision too high?
Palvella Therapeutics' current Tax Provision is €0.00 Mil. Overall, Palvella Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Palvella Therapeutics' Tax Provision compare to GENB and NKTR?
Palvella Therapeutics' Tax Provision of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Palvella Therapeutics and its competitors. Palvella Therapeutics's current Tax Provision is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palvella Therapeutics stock overvalued right now?
Palvella Therapeutics (FRA:PI6) has a current Tax Provision of €0.00 Mil. The current Tax Provision is €0.00 Mil. Palvella Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Palvella Therapeutics (FRA:PI6), the current Tax Provision is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palvella Therapeutics Business Description

Other Exchanges PVLA:USA
Address 353 W. Lancaster Avenue, Suite 200, Wayne, PA, USA, 19087
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
20GF Score

Get the complete analysis for FRA:PI6

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€125.00
Price